The SAFE study: a landmark trial of the safety of albumin in intensive care

Med J Aust. 2004 Sep 6;181(5):237-8. doi: 10.5694/j.1326-5377.2004.tb06258.x.


High-quality primary evidence from an Australian and New Zealand study provides a definitive answer.

Publication types

  • Editorial

MeSH terms

  • Albumins / adverse effects*
  • Australia
  • Critical Care
  • Hospital Mortality
  • Humans
  • Intensive Care Units
  • Length of Stay
  • New Zealand
  • Randomized Controlled Trials as Topic


  • Albumins